deucravacitinib + ritonavir

**Deucravacitinib + ritonavir** is a combination of deucravacitinib (BMS-986165), an oral, highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2), and ritonavir, an antiretroviral agent primarily used as a pharmacokinetic booster due to its potent inhibition of CYP3A enzymes. Deucravacitinib is indicated for treatment of immune-mediated diseases and acts by blocking IL-12, IL-23, and type I interferon signaling, thus modulating inflammatory and immune responses. Ritonavir is included to affect the pharmacokinetics of deucravacitinib by inhibiting its metabolic breakdown through CYP3A, increasing systemic exposure. This combination is not a marketed product but represents a pharmacological regimen in clinical study settings to investigate interactions and optimize deucravacitinib dosing.

Other names

deucravacitinib + ritonavirBMS-986165 + ritonavir